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Introduction
Two 52-year-old patients, one female and one
male, in otherwise good health, presented with
urinary urgency, frequency and nocturia. No phys-
ical or laboratory abnormalities were noted. The
female patient was treated with an antimuscarinic
for her presumed overactive bladder (OAB), while
her male counterpart was prescribed an alpha
blocker for his presumed benign prostatic hyperpla-
sia (BPH). Why is it that these two patients, pre-
senting with the exact same lower urinary tract
symptoms (LUTS), would so commonly receive
different initial therapies? Because obstruction is a
highly unlikely cause of LUTS in the otherwise
healthy female patient, OAB is a reasonable
assumption. However, in the male patient, the ini-
tial empiric diagnosis of BPH may be correct, but
the fact remains that not all cases of male LUTS
equate to BPH.
It is only in recent years that urologists have
begun acknowledging OAB as an independent cause
of LUTS in males. It has taken time (for the trickle
down) for primary care physicians (PCPs) to
become similarly comfortable with recognising and
safely treating OAB in the male patient. The evi-
dence supports this shift in our understanding of
LUTS in males. One study showed that 43% of
older men with LUTS suffer from detrusor overac-
tivity (DO), not bladder outlet obstruction (BOO)
(1), and only 50% of men with preoperative DO
will have resolution of DO after outlet reduction
surgery (2). In another study, Kaplan et al. (3)
showed that the majority of men under 50 years of
age with LUTS do not, in fact, have BPH; their
symptoms are likely attributable to another cause.
Understanding this paradigm shift has important
implications for patient care. Regardless of the
underlying cause, if the patients’ symptoms are not
resolved as a result of prescribed therapy, they may
suffer needlessly or even undergo unnecessary pros-
tate surgery.
As the first to encounter these patients, the PCP is
in a unique position to provide needed counselling
SUMMARY
Aims: Lower urinary tract symptoms (LUTS) are common in both men and women,
and are among the most prevalent patient complaints heard by primary care physi-
cians (PCPs). This article aims to provide PCPs with a logical algorithm for the
assessment and initiation of treatment for LUTS in the male patient. Results:
Management of LUTS involves a focused history and physical, as well as the
assessment of bother. In patients for whom treatment is warranted, a series of
decisions regarding therapy should be considered. Male patients commonly suffer
from storage and/or voiding symptoms. Treatment of male LUTS is commonly
begun with agents that are aimed at remedying the outlet symptoms of benign
prostatic hyperplasia (BPH). When this intervention is ineffective or when refractory
symptoms persist, consideration should be given to treating the storage symptoms
characteristic of overactive bladder (OAB). Discussion: This article is intended to
provide the PCP with a logical guide to the treatment of male LUTS. Benign pro-
static hyperplasia and OAB predominate among the causes of these symptoms,
and the PCP should be comfortable treating each. Recent data detailing the safety
of the use of these treatments in the male patient are reviewed and incorporated
into the algorithm. Conclusion: Primary care physicians are in a unique position
to successfully identify and treat male patients with LUTS. With this paper, they
now have a tool to approach treatment logically and practically.
Review Criteria
Male patients experiencing LUTS are likely to suffer
from BPH. Recent evidence confirms, however, that
these patients may solely or additionally suffer from
OAB. Moreover, it has been shown that
antimuscarinic therapy can be both effective and
safe in these patients.
Message for the Clinic
Primary care physicians are provided with a simple
and logical approach to treating LUTS in the male
patient. This algorithm provides a guide that
enables the PCP to effectively deduce the
opportune points for treatment with multiple
classes of drugs or referral to a specialist.
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and intervention (4). Doing so appropriately, how-
ever, requires that we look beyond the current
dogma that LUTS in the male equates to BPH. The
purpose of this paper is to present a new algorithm




According to the International Continence Society
(ICS), LUTS can be divided into storage symptoms,
voiding symptoms and symptoms experienced post-
micturition (Table 1) (5). As is evident from the
table, storage symptoms tend to be irritative in nat-
ure, whereas voiding symptoms have a more
obstructive cause.
Interestingly, LUTS in the male are usually attrib-
uted to BPH. As a result of this preset notion, men
with LUTS are predominantly treated with alpha-
adrenergic medications. Alternatively, LUTS in the
female are predominantly attributed to OAB, and are
thus treated with anticholinergic medications. To
provide optimal care, PCPs must consider the full
spectrum of conditions that can result in LUTS in
every patient.
Definition of BPH
The term ‘BPH’ can be difficult for the provider, as
it carries several interpretations and has become idio-
matic over the years for a ‘troublesome prostate.’ In
reality, BPH is the most likely, but not the only, con-
dition from which male patients may experience
LUTS. There are also subtle differences in accepted
terminology that should be reviewed. The term
‘BPH,’ in fact, refers to the asymptomatic micro-
scopic detection of prostatic hyperplasia, the benign
proliferation of the prostatic stroma and epithelium.
The palpable enlargement of the prostate gland,
which can be diagnosed with clinical or ultrasound
examinations, is called benign prostatic enlargement.
Enlargement of the prostate that is accompanied by
LUTS, when prostatic hyperplasia affects urinary
flow, is referred to as benign prostatic obstruction
(6,7). For the PCP, these differences in terminology
are important to know when evaluating the litera-
ture, but are largely irrelevant in clinical practice.
Therefore, for the sake of clarity, the authors will use
the term ‘BPH’ to refer to the complex of symptoms
experienced as a result of the troublesome prostate.
Definition of OAB
Overactive bladder is defined by the ICS as a
syndrome including urinary urgency (the intense,
sudden desire to void) with or without incontin-
ence, urinary frequency (voiding too often during
the day) and nocturia (awakening at night to void)
(8,9). The symptoms of OAB are present in the
absence of any pathologic or metabolic disorders
that might otherwise result in symptoms. Together,
BPH and OAB result in the overwhelming majority
of cases of male patients with LUTS that present
PCPs.
Pathophysiology
Lower urinary tract symptoms has a varied patho-
physiology that may be multifactorial. While OAB is
a symptom complex generally of unknown aetiology
(with numerous theories), the voiding symptoms of
BPH are presumably caused by prostatic enlargement
that interferes with urinary flow. The aetiology of
storage symptoms of BPH, however, remains contro-
versial.
Pathophysiology of OAB
To understand the abnormal function suffered by the
patient with OAB, it is instructive to start with nor-
mal bladder function. Micturition involves two
important, yet discrete processes: (i) bladder filling
and storage and (ii) bladder emptying (10). Nor-
mal bladder capacity is 300–400 ml of urine (9).
Table 1 Lower urinary tract symptoms
Storage symptoms Voiding symptoms Postmicturition
Frequency Slow stream Feeling of incomplete emptying
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Normally, adults first experience the urge to void
before capacity reaches 200 ml (9,11). Second urge
occurs later, at near-normal capacity, and the non-
affected patient can generally hold off micturition for
a reasonable amount of time to reach an appropriate
facility. The filling and storage phase requires accom-
modation of increasing pressures with appropriate
sensation, a closed bladder outlet and absence of
involuntary contraction. For the bladder to empty,
there must be a co-ordinated contraction of the
bladder muscle, a lowering of the resistance of the
outlet, and an absence of anatomic obstruction. Any
type of voiding dysfunction can be classified by
an abnormality of any one or more of these three
factors.
The aetiology of OAB is heterogeneous, but the
commonality is the inability to accommodate the
increasing volumes of urine, with the increased sen-
sation causing symptoms of urgency and frequency
with or without a contraction. The urgency associ-
ated with OAB is defined as sudden, intense and
difficult to deter. This is different from the normal
urge sensation that still offers adequate time to pre-
pare for voluntary micturition. Storage symptoms
may result from abnormal signalling, a sensory
amplification (afferent) or increased motor output
(efferent).
Pathophysiology of BPH
The hyperplastic prostate, as a result of its close
proximity to the urethra, can affect urinary flow
by obstructing the urethra. This leads to the classic
voiding symptoms associated with BPH: reduced
stream and intermittency. Prostate enlargement,
however, can also lead to overactivity of the detru-
sor muscle. It is unclear to what extent prostatic
hyperplasia and obstruction incur storage symp-
toms (12).
Relationship of BPH and OAB
Figure 1 addresses LUTS and its relationship with
BPH and OAB. OAB will always cause LUTS (by
definition); BPH will sometimes cause LUTS. The
two can also co-exist. Figure 1 graphically represents
the relationship of OAB and BPH in the context of
LUTS.
Impact (incidence/prevalence, quality
of life, social implications)
As a result of high prevalence, the PCP is extremely
likely to encounter LUTS among adult male patients.
Stewart et al. (13), as part of the National Overactive
BLadder Evaluation Programme, a large-scale epi-
demiologic survey of community-based adults over
the age of 18, demonstrated that OAB occurs in
16–17% of Americans. Not surprisingly, the preval-
ence of OAB with urge incontinence increased with
age. Perhaps less expected, however, was the fact that
men were as likely to suffer from OAB as women,
although women were more likely to report incontin-
ence as a symptom.
Microscopic BPH affects approximately 50% of
men 50–60 years of age (14), 75% of men 60–69
years of age and up to 90% of men over the age of
80 (15). This suggests that, in the USA alone, as an
example, some 25 million men have a hyperplastic
prostate (16). However, we have established that
having a hyperplastic prostate does not equate to
experiencing symptoms. It has been estimated that 9
million American men are affected by bothersome
symptoms resulting from BPH (17).
For each of these increasingly prevalent conditions,
the impact on the patient is substantial. LUTS can
significantly reduce quality of life (18,19). Patients
may resort to social isolation, become depressed,
have reductions in productivity, experience poor
sleep and often have an impaired sex life. LUTS is
associated with the development of sexual dysfunc-
tion and ejaculatory problems, but impaired sex life
can also be a result of the psychological implications
of LUTS (9,19).
Furthermore, LUTS have significant economic
implications. Direct costs associated with diagnosis
and treatment make up the majority of this econo-
mic burden, but indirect costs can also be significant.
Indirect costs include incidence of absenteeism
(missing work) and presenteeism (decreased produc-
tivity at work). The estimated direct cost alone of
BPH in males in the USA is $1.1 billion (15). More-
over, the pharmacologic treatment of LUTS, no
Figure 1 The relationship between overactive bladder
(OAB) and benign prostatic hyperplasia (BPH) in the
context of lower urinary tract symptoms (LUTS)
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matter the underlying cause, has been shown to be
economically cost effective (20,21).
Clinical presentation – using the
algorithm
Differential diagnosis and other causes of LUTS
The utilisation of the clinical algorithm (Figure 2)
proposed in this paper begins with differential diag-
nosis, ruling out other causes that require medical
attention, and identifying contributing and/or preci-
pitating factors. LUTS are not specific to any one
entity and many urologic and non-urologic condi-
tions can cause LUTS. Table 2 shows diagnoses in
addition to BPH and OAB that the clinician must
consider, medications that can cause or exacerbate
urinary symptoms, and other risk factors for the
development of LUTS.
Figure 2 Clinical algorithm for the assessment and initiation of treatment of male lower urinary tract symptoms (LUTS)
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It is essential that the provider keep the differential
diagnosis for LUTS in mind during the evaluation of
the patient. Certainly, OAB and BPH are common,
but one should avoid making a premature judgment.
In the following section, we analyse the algorithm for
evaluation and treatment of LUTS in the male
patient. One proceeds with the algorithm only if no
other pathologies that could result in LUTS are iden-
tified.
Evaluation
The algorithm presented is designed for the PCP
who is generally the first point of contact for the
male patient with LUTS. It is not meant to address
all possible contingencies, but rather to provide a
logical framework from which one can initiate ther-
apy or know when to refer. The authors believe that
LUTS in men can be treated in the primary care set-
ting; the algorithm provides a basis and direction for
this practice to occur.
Identifying LUTS
The first challenge is to identify LUTS. This could
possibly be the most difficult part of the evaluation,
as patients can be quite reticent to proactively bring
up these symptoms. Patients are likely to be embar-
rassed, believe that their symptoms are a normal part
of ageing, or even fear surgery. Screening tools exist
to help evaluate LUTS, however they may not always
be practical in a busy primary care setting. In one
study, it was shown that 2/3 of PCPs were aware of
the American Urological Association (AUA) symp-
tom score, but only 1/3 used it (4). Another screen-
ing tool, the International Prostate Symptom Scoring
(IPSS) sheet, does have the advantage that it is uni-
versal and has been validated. Because other condi-
tions can produce similar symptoms, however, it
cannot be used as a diagnostic tool (24). The IPSS
ideally would be used by all clinicians at this junc-
ture, but, as an alternative, a few simple questions
can also direct the physician to the disease.
History, physical and laboratory evaluation
Once LUTS have been identified, it is necessary to
proceed with a focused history and physical, as well
as a few laboratory tests. The goal of this evaluation
is to identify other causes of the LUTS, possible
reversible issues or comorbidities that may compli-
cate treatment. The PCP has a distinct advantage
over the specialist of having prior knowledge of the
patient, making the information needed for the his-
tory readily available. For example, first-hand know-
ledge of recent changes in medications, family
history or prior surgeries may expedite identifying a
cause of LUTS.
A key to the proper evaluation of LUTS is to give
special attention to the voiding volume that the
patient produces. If the patient voids small amounts
of urine frequently, then the urologic function is
more likely to be abnormal. However, if the patient
voids normal amounts frequently, then a medical
cause is more likely than a urologic cause. Nocturnal
polyuria, which is a potential cause of nocturia, is a
good example of this concept. The definition of noc-
turnal polyuria is when more than 20% (in ‘young
adults’) or more than 33% (in those older than
Table 2 Lower urinary tract symptoms (LUTS): differential diagnosis and other causes (22,23)
Differential diagnosis Medications Other risk factors
Consider: May cause or exacerbate LUTS: Consider:
Bladder cancer Tricyclic antidepressants Obesity
Prostate cancer Anticholinergic agents Cigarette smoking
Prostatitis Diuretics Regular alcohol consumption
Bladder stones Narcotics Elevated blood pressure










CHF, congestive heart failure.
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65 years) of a person’s total 24-h urine production
occurs at night (25). This is neither a storage nor a
voiding symptom, because the bladder is behaving
normally by holding and emptying a normal capacity
of urine.
The physical examination should likewise be
focused. One first conducts an abdominal examina-
tion to evaluate for tenderness, masses or an overdis-
tended bladder, followed by a brief, focused
neurological examination to check for patient’s men-
tal and ambulatory status and neuromuscular func-
tion. Next, the provider should conduct a thorough
examination of the genitalia, including the meatus
and testes. A digital rectal examination to evaluate
rectal tone and prostate size, shape and consistency
will provide the opportunity to detect prostatic
implications in symptoms (24). Much of the physical
examination may have been done at prior visits with
the PCP, so that re-examination (i.e. prostate exam)
may not be necessary. Again, one of the benefits to
the PCP is that the patient’s medical information
and baseline physical examination is usually known.
A urinalysis performed by dipstick or microscopic
examination is strongly recommended to check for
blood, protein, glucose or any signs of infection. This
may prompt treatment or referral (26). Although
haematuria or pyuria is not always found in condi-
tions such as bladder cancer, stones or infection, a
normal urinalysis makes these diagnoses less likely
(26). A prostate-specific antigen (PSA) measurement
should be offered to age-appropriate males and refer-
ral made if abnormalities are found. Although not
part of the AUA guidelines, there is a good argument
for testing blood sugar, either random or fasting.
Generally, a patient does not spill glucose into the
urine until the blood sugar is > 180 mg/dl
(10 mmol/l). Consequently, a dipstick urinalysis may
fail to pick up on intermittently high sugars or mild
diabetics (26). Urine cytology is optional, but may
be performed prior to referral for evaluation of hae-
maturia and may be considered in men with storage
symptoms or at risk for bladder cancer (26).
Although once recommended, serum creatinine is no
longer indicated (26).
Any abnormalities found during the history, phys-
ical or laboratory evaluation that could possibly con-
tribute to LUTS should be addressed by the clinician
or referred to a urologist. Table 3 lists reasons for
referral at this juncture. If none of these abnormalit-
ies are identified, it is appropriate to proceed with
assessment of bother.
Assessing bother
If the evaluation thus far reveals no other aetiology
for the LUTS, the next step is to assess bother. As
mentioned earlier, there are tools to assist in assess-
ment of symptoms and bother. It is acknowledged
that the validated scores (IPSS or AUA symptom
index) are superior to an unstructured interview in
quantifying symptom frequency and severity (26).
Nevertheless, the practicality of these items in the pri-
mary care office can be questioned. Perhaps more
importantly, a few simple yet pertinent questions can
expedite care. This assessment should be left to the
discretion of the provider. One of the authors (MTR)
finds one simple question can be enough: ‘Are your
symptoms bad enough that they would justify taking
a medication each day or having a surgical proce-
dure?’ In the clinical opinion of this author, most
patients will answer honestly and appreciate being
part of the process. A similar question from the valid-
ated IPSS scale (27) measures quality of life as it is
affected by BPH: ‘If you were to spend the rest of
your life with your urinary condition just the way it
is now, how would you feel about that?’.
If assessment, by whatever means, reveals minimal
bother then watchful and informed waiting is appro-
priate. ‘Informed waiting’ refers to the idea that the
patient is knowledgeable of the symptoms or compli-
cations that may occur. If assessment leads to a
decision to proceed with treatment, the clinician
must then assess whether symptoms result from
OAB or BPH. It should be noted that an assessment
for haematuria, recurrent urinary tract infection
(UTI), elevated PSA, neurological conditions and
retention should be initiated based on risk irrespect-
ive of LUTS.
Is it OAB or BPH?
When dealing with the clinical presentation of LUTS,
the clinician must first differentiate between storage
and voiding issues, which were summarised earlier in
Table 1. The reality is the provider cannot make a
definitive diagnosis of obstruction without advanced
Table 3 Indications for referral
History of recurrent urinary tract infections or other infection
Microscopic or gross haematuria
Prior genitourinary surgery
Elevated prostate-specific antigen
Abnormal prostate exam (nodules)
Suspicion of neurologic cause of symptoms
Findings or suspicion of urinary retention
Meatal stenosis
History of genitourinary trauma
Uncertain diagnosis
Pelvic pain
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testing, such as urodynamics. This algorithm recom-
mends making a provisional diagnosis using clinical
judgment and a consideration of safety. We know
that storage issues affect the bladder and the ability
to hold urine, whereas voiding issues relate to
obstruction and urine expulsion. If voiding symp-
toms such as poor flow or intermittency exist, then
an obstructive cause is more likely the problem, and
the focus is placed on the prostate. However, if stor-
age seems to be the issue (as seen in urgency, fre-
quency, etc.), one may consider OAB as a diagnosis.
Of course, it is important to note that many patients
exhibit both OAB and BPH, which must be consid-
ered when evaluating the path one takes through the
algorithm.
Provisional BPH: behavioural and
pharmacological therapy
As we proceed with the algorithm, the reader will
notice that the arrow to the provisional diagnosis of
BPH is larger than that to OAB. There are many rea-
sons for this. The most important is that the authors
believe that this clinical path is the most practical for
the PCP, as minimal testing is required. It also fol-
lows typical practice patterns (4,28). Furthermore, an
enlarged prostate may be the cause leading to the
OAB. While there are tests that may aid in the decis-
ion-making process, such as pressure-flow studies
and postvoiding residual (PVR) urine measurement,
the recent AUA guidelines state that these are not
necessary prior to the institution of medical therapy
(26). Empiric medical therapy is appropriate at this
juncture, but the provider must also consider the
benefits of behavioural modification.
Behavioural modification can take several forms.
Some patients benefit from improving access to the
bathroom or a toilet. Some find assistance with
decreased fluid intake. Diet can also play a role. One
study suggested that increased intake of high energy
foods (foods containing a large amount of caffeine)
and protein may be a risk factor for BPH (29). Alter-
natively, another study found that a diet rich in veg-
etables and beta carotene, lutein and vitamin C may
reduce the occurrence of BPH (30). Although dietary
counselling may be outside the PCP’s specialty, it is
important to know that some data on this topic do
exist, especially considering that patients are likely to
find information about this in the lay press.
The medication armamentarium for the PCP in
the treatment of BPH consists of alpha blockers and
5-alpha reductase inhibitors (5ARIs). Although there
are other therapeutic modalities such as phytothera-
py, they will not be discussed here.
Alpha blockers treat the ‘dynamic’ component of
BPH, offering fast relief of symptoms (31). The
mechanism is to inhibit activation of alpha1 adrener-
gic receptors, which results in relaxation of prostatic
and bladder neck smooth muscle and thus decreases
LUTS (32). Frequently prescribed alpha blockers are
alfuzosin, doxazosin, tamsulosin and terazosin. All
four agents have comparable efficacy (26). Alfuzosin
and tamsulosin are clinically uroselective, thereby
resulting in fewer cardiovascular effects (i.e. vasodila-
tory adverse events) (33). Some patients may have
specific comorbidities or characteristics that would
lead to choosing one alpha blocker over another. For
example, as a significant number of elderly men have
hypertension, these men may derive benefit from a
mixed subtype alpha blocker such as doxazosin or
terazosin, both of which have been shown to reduce
blood pressure levels in hypertensive men without
affecting blood pressure levels in normotensive men
(34,35). It should be noted, however, that using dox-
azosin or terazosin for this type of dual treatment
has gone out of favour because of the advent of
newer antihypertensive medications.
Five-alpha reductase inhibitors act on the ‘static’
component of the prostate by inhibiting the conver-
sion of testosterone to dihydrotestosterone, thereby
limiting prostate growth. The two medications in this
class are finasteride and dutasteride. Both are effect-
ive when used in the patient with LUTS that are
associated with demonstrable prostate enlargement
(26). In particular, both have been noted to reduce
the risk of acute urinary retention and the need for
prostate surgery (36). The disadvantage of these
agents is that they require long-term daily therapy
(up to 6 months) before symptom relief is achieved
(26). Moreover, the use of these agents can be com-
plicated for the PCP, as these agents lower the serum
PSA and, thereby, change screening parameters.
At this point in the algorithm, patient bother has
been identified and most physicians believe that it is
best to initiate therapy with an alpha blocker as
opposed to a 5ARI, as these medications are most
likely to provide immediate response. If successful,
symptom resolution with alpha blocker therapy
should occur within 2–4 weeks. If so, then periodic
follow-up is all that is necessary. If the patient is
adherent to the prescribed regimen, but it falls short
of anticipated goals, one is left with the opportunity
to use a 5ARI or to shift diagnosis. If the alpha block-
er has provided some relief and the prostate is pal-
pably enlarged, it is reasonable to try prostatic
reduction via the 5ARI (26). It has been noted that
men with bothersome LUTS and an enlarged prostate
(> 30 ml) or a PSA > 1.4 ng/ml have an increased
risk of complications such as acute urinary retention.
Studies have shown that initiating dual therapy with
an alpha blocker and a 5ARI may be advantageous in
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these patients (24,37). It is critical, however, for the
patient and the physician to accept this as a ‘long-
term’ plan as response to 5ARI therapy may take up
to 6 months and will need to be continued.
An important point to consider is that the alpha
blocker may not have actually failed in relieving
obstruction. It is also plausible that the most bother-
some symptoms may be a result of storage complica-
tions (i.e. OAB) and, as such, this therapy was either
not appropriate or did not provide complete relief.
OAB symptoms may be exacerbated by BOO that
results from BPH (38). Alternatively, if the alpha
blocker fails to reduce LUTS at all, then additional
diagnosis such as OAB should be considered. In gen-
eral, men report that these medications do improve
urinary flow and nocturia, but not urgency or fre-
quency. In either of these scenarios, or any time
OAB is considered, the algorithm recommends asses-
sing the PVR. If this cannot be performed in the
office of the PCP, the patient may be better served
by referral to a urologist or other facility that can
evaluate PVR (i.e. outpatient diagnostic center).
Provisional OAB
If the symptoms identified in the initial patient eval-
uation are more consistent with storage than voiding,
the provisional diagnosis of OAB can be made. Simi-
larly, if treatment for BPH proves ineffective, one
can move to the OAB section of the algorithm to
either shift diagnosis or add treatment for OAB.
Unfortunately, with the treatment of OAB comes the
possibility of placing a patient at risk of, or worsen-
ing a condition of, retention. In fact, the package
insert for every antimuscarinic includes a warning
that these agents should be used with caution in
patients with BOO, and that they are contraindicated
in patients with urinary retention. The terms ‘retain-
ing urine’ and ‘retention of urine,’ and ‘BOO’ and
‘urinary obstruction’ have not been quantified. The
dictum that anticholinergics in the male are to be
‘utilised with caution’ or are ‘contraindicated’ does
not specify the amount of residual urine or the
degree of outlet resistance that would put a patient
at risk of further deterioration of clinically significant
problems with bladder emptying. The evidence either
way is lacking, and further studies will need to be
performed to elicit the truth. However, it is this con-
cern that leads to the recommendation of PVR
assessment when considering treatment for OAB.
Measuring PVR
The measurement of PVR has been uniformly
recommended in the literature as a useful screening
tool for the male patient with LUTS (12,24,26),
although these recommendations fall short of man-
dating its use. There may be many reasons for this.
First, it is known that intra- and interindividual vari-
ability exists (24,39). Furthermore, as is the case for
flow-rate testing, measurement of PVR does not dis-
tinguish obstruction from underactive bladder, nor
does it correlate with urodynamic evidence of the
severity or duration of obstruction (39). Even though
large PVR volume may indicate bladder dysfunction
and herald progression of disease, clear-cut parame-
ters for decision making, as yet, do not exist (26).
The AUA guidelines note that many patients main-
tain a significant PVR volume without evidence of
UTI, renal insufficiency or bothersome symptoms. It
is concluded, therefore, that no level of residual urine
mandates invasive therapy.
Keeping all of this in mind, what does this mean
for the PCP, and does the use of PVR measurement
help? The algorithm notes that the goal at this junc-
ture is to attempt to delineate the cause of LUTS;
that is, whether the patient suffers from obstruction
or from OAB. The obvious concern to the PCP is
the possibility of missing the patient who is in
retention or predisposed to it. To better account for
these possibilities, the authors advocate the use of
PVR. This may increase the comfort level of the PCP
and thereby facilitate care. A clinically reasonable
approximation of PVR can be made via transabdom-
inal ultrasonography, portable bladder scanner or
urethral catheterisation. Although there may be some
variability in the precision data for portable bladder
scanners (40), studies have confirmed their clinical
accuracy (41,42), and they are more than adequate
for the purpose of instituting therapy. In fact, a
recent study found that a three-dimensional hand-
held scanner measured bladder volume more accu-
rately than by using two-dimensional stationary
ultrasonography (43). Bladder scanners are routinely
used by urologists and acute care hospitals to deter-
mine bladder volume, and they provide a reasonable
option for the office-based PCP. We propose a logi-
cal approach to using PVR to assist the PCP in the
evaluation and treatment of LUTS.
PVR £ 50 ml
It is reasonable to believe that the patient with a
minimal volume noted on PVR is at decreased risk
for retention. We must then define minimal volume
for the purposes of this algorithm. A review of the
literature offers only limited help in defining this
value, suggesting that further research on this topic
is needed.
McNeill et al. (39) examined the correlation
between PVR and clinical efficacy of an alpha blocker.
In 953 patients followed, only seven went into retent-
ion during the study, two in the medication group
1542 Practical guide to evaluating and treating male LUTS in primary care
ª 2007 The Authors
Journal compilation ª 2007 Blackwell Publishing Ltd Int J Clin Pract, September 2007, 61, 9, 1535–1546
(0.3%) and five (1.3%) in the placebo group. Six of
the seven that went into retention had a baseline PVR
of > 100 ml. In the Olmsted County study (40), it
was found that a PVR of > 50 ml at baseline resulted
in a threefold increase in the risk for urinary retent-
ion. It is the opinion of the authors that the more
conservative, and subsequently safer, PVR of £ 50 ml
puts the patient at minimal risk for retention and
should be utilised by the PCP. If the PVR is noted to
be £ 50 ml, then the next step would to be to consi-
der urinary flow (uroflow), which will be discussed in
the following section.
PVR > 50 ml
It is conceivable that some PCPs may wish to adopt
a higher cut-off value for the treatment of LUTS
than the £ 50 ml recommended in this algorithm
(9). This is not unreasonable given the findings by
McNeill et al. (39) and the comfort level that some
PCPs have with LUTS, BPH and OAB. Nevertheless,
for PCPs who lack this experience or the comfort
to treat these patients, it is the recommendation of
the authors that patients with a PVR > 50 ml be
referred to a specialist. One author (DN) recom-
mends that if the PVR is elevated, the PCP may
want to repeat the PVR at another visit to verify its
validity.
Evaluating uroflow
In patients for whom the PVR is £ 50 ml, the next
step is to evaluate uroflow. The benefit of uroflow
testing in LUTS is not necessarily to point to BPH as
a cause, but rather to exclude it as a diagnosis. One
cannot say that a poor flow correlates with obstruc-
tion as this can also be caused by inadequate detru-
sor function. Nevertheless, it is reasonable to
conclude that in a male with good flow the diagnosis
of obstruction is unlikely (24).
Attaining a uroflow in the office of the PCP may be
difficult and impractical. In a perfect world, every PCP
would have access to a monitoring device; however,
this is obviously not the case. It is the opinion of the
authors that most men can give a fairly accurate self-
evaluation of stream and that this often will suffice.
To assist patients with the self-evaluations of their
own urinary flow, the PCP can use helpful termin-
ology, such as ‘weak’ or ‘slow stream,’ ‘interruption of
stream,’ ‘hesitancy in starting stream’ or ‘dribbling’.
Weak flow rate
Studies suggest that a very low flow rate (< 8 ml/s)
is highly predictive of BOO (44). It is the opinion of
the authors that such cases should be referred to a
urologist.
Good flow rate
A good flow effectively reduces the likelihood of
obstruction as a diagnosis and should place the
focus of the provider on storage issues (bladder
dysfunction). It is at this point that one should
consider the diagnosis of OAB as the cause of the
LUTS. It is difficult to offer an absolute measure-
ment for ‘good flow,’ which can be defined as a
smooth, arc-shaped curve with high amplitude as
seen with uroflowmetry. As opposed to a weak
flow, which would be interrupted, a good flow
would not be interrupted, flat, asymmetric or have
multiple peaks (45). Uroflowmetry can be useful by
testing for these characteristics, but this may not be
a tool that is available to most PCPs. Therefore, the
PCP should be able to evaluate flow effectively
simply by using terminology such as that men-
tioned above.
Treatment of OAB: behavioural and
pharmacologic therapy
Behavioural therapy
The foundation for treating the patient with OAB
is behavioural modification. The goal is to teach
the patient the normal process of micturition and
the mechanism by which symptoms define an
abnormal physiology. Behavioural therapy should
begin with patient education, but also can include
bladder retraining and urge suppression techniques,
dietary alterations, changing the timing of various
concomitant medications (e.g. diuretics), and
encouraging exercise and weight loss. Although
most patients will require the addition of drug
therapy, urinary incontinence literature shows that
the combination of both behavioural and pharma-
cological therapies provides the greatest likelihood
of positive outcome, compared with either interven-
tion alone (46).
Pharmacologic therapy
The principle of pharmacologic management of OAB
is to inhibit DO via antimuscarinic therapy. These
agents exert their clinical effect through antagonistic
action at cholinergic receptors on the detrusor mus-
cle, preventing unwanted muscle contraction result-
ing from the parasympathetic acetylcholine release.
As these agents are competitive antagonists, their
effect is removed during the massive parasympathetic
release of acetylcholine, which occurs with normal
micturition, allowing for normal physiology (47).
Antimuscarinics work via two potential roles: one on
the motor pathway via central and peripheral actions
that block a facilitory mechanism and stimulate an
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inhibitory mechanism, and on the sensory pathway
via central and peripheral actions that modulate
afferent innervations.
Researchers and clinicians have provided signifi-
cant contributions to the literature that support the
diagnosis of male OAB, as well as showing therapy
can be safe. A pivotal study by Abrams et al. (38)
reported the results of utilisation of anticholinergic
agents in selected male patients. In this study, men
with elevated residuals (> 40% of maximum cysto-
metric capacity) or prior genitourinary surgery (sim-
ilar to our algorithm) were excluded and those
remaining were offered antimuscarinic therapy. Urin-
ary retention was reported only in one patient in the
placebo group and the incidence of adverse events in
those receiving medication was similar to those
receiving placebo. Patients receiving anticholinergic
therapy had significant improvement in bladder
capacity, and increases in volume to first detrusor
contraction and maximum cystometric capacity. The
authors concluded that antimuscarinic therapy is safe
and tolerable in men.
Five oral antimuscarinics have been approved for
treatment: darifenacin, oxybutynin, solifenacin, tolter-
odine and trospium. Long-acting extended versions
of these medications have better tolerability and tit-
ratable doses can be beneficial (48,49). The side
effects of dry mouth and constipation are comparable
with all the medications. There is currently a trans-
dermal form of oxybutynin that limits the side effects
of dry mouth and constipation, but has the adverse
effect of skin irritation in certain patients. There are
substantial data showing the safety of these drugs in
male patients. All of them were reviewed for safety in
men with BPH or BOO in a 2006 systematic review
and meta-analysis by Blake-James et al. (50).
The patient and provider will generally be able to
identify symptom relief within 2–4 weeks. On fol-
low-up, it is prudent to check PVR to verify no
retention of urine has occurred. If volume is £ 50 ml
and the patient is satisfied, then continuation of
medications with periodic follow-up is appropriate.
The patient should be made aware that failure to
void or a feeling of incomplete voiding is reason for
urgent follow-up. If the symptoms are not resolved
and the PVR is £ 50 ml, then the provider may want
to increase the dose of medications, switch medica-
tions or refer. An evaluation of PVR > 50 ml is a
reason to stop medication and seek a urologic con-
sultation. However, some providers may wish to
allow a slightly higher PVR, as the choice of 50 ml is
somewhat arbitrary given that no specific value has
been studied. For physicians who choose to utilise a
more liberal PVR, we recommend close follow-up
and more frequent evaluation of PVR.
Combination therapy
A brief note on combination therapy is prudent
here, as the male patient frequently suffers from
both OAB and BPH. As mentioned earlier, it is not
uncommon for alpha blocker therapy to fail for
reasons other than improper diagnosis. The
patient’s bothersome storage symptoms can be
exacerbated by BPH (38). Although there is no for-
mal guidance for the use of combination therapy,
the conscientious provider may be able to elicit
symptoms of both storage and voiding and treat
appropriately as indicated. In a prospective study,
144 consecutive men with symptomatic and urody-
namically confirmed BOO were subdivided into
those with pure BOO (53%) and those with BOO
plus DO (47%) (51). After the initial evaluation, all
patients were treated with the alpha blocker doxazo-
sin in escalating doses up to 4 mg/day for
3 months. Patients from both groups (with or with-
out DO) who reported no improvement in symp-
toms were then assigned to combination therapy,
which included immediate-release tolterodine 2 mg
twice daily for an additional 2 months. Among men
in the BOO + DO group, at the end of the initial
3-month treatment period with doxazosin alone,
65% reported no improvement and were then pro-
vided combination therapy. Of these patients
assigned to combination therapy, 73% reported
symptomatic improvement.
A 2005 open-label study evaluated the safety and
efficacy of extended-release tolterodine in male
patients with LUTS and in whom alpha blocker ther-
apy had failed previously. After 6 months, the AUA-
symptom score improved from 17.3 at baseline to
11.2 at 6 months. Of critical importance for the PCP
is that no patients developed acute urinary retention
(52).
Conclusions
There is conclusive evidence that many men are
affected with LUTS. Here, we have reviewed data
that show many of these men have OAB as the caus-
ative factor, rather than the traditionally thought
BPH, although both are common. The majority of
symptomatic men do not get treated (53). One can
speculate on the many reasons for this lack of identi-
fication and treatment. Gaps in education, awareness
and a lack of simplified screening tools may be at
fault. Alternatively, providers may incorrectly assume
that if LUTS were a problem, the patient would
bring it up. Lastly, PCPs may fear that extensive eval-
uation will ‘open a can of worms’ with which they
do not wish to deal.
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This algorithm is proposed not as the ‘end all’ for
the evaluation of LUTS in men, but as one mechan-
ism to better facilitate proper evaluation of these
patients. While many urologists might find it overly
simple, it is intended only as a logical framework for
evaluation and is intentionally kept simple to facili-
tate its use in the office of the busy PCP. Clearly, the
PCP is the first line of contact for most of these
patients. Men can be safely treated for LUTS in the
PCP office, thereby saving the refractory cases for the
specialist. If this were to occur, at least theoretically,
more male patients with LUTS could be treated
effectively and efficiently. This, in turn, could
improve troublesome symptoms, and therefore qual-
ity of life, for those affected.
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